Invitro International (IVRO) Osake Kurssi

Invitro International is primarily active in the biomedical research and healthcare industries.

The main competitors of Invitro International in the market are companies like Thermo Fisher Scientific, Charles River Laboratories, Laboratory Corporation of America Holdings (LabCorp), and Eurofins Scientific.

Invitro International is a renowned company that specializes in developing and providing in vitro testing solutions for the cosmetic, chemical, and pharmaceutical industries. Established in 1977, Invitro International has been a pioneer in the field of non-animal testing methods. The company's commitment to ethical and sustainable practices has led to the development of innovative and reliable testing solutions, including alternative methods to animal testing. Invitro International is dedicated to helping its clients meet regulatory requirements while reducing their reliance on animal testing. With a rich history spanning over four decades, Invitro International continues to be a trusted partner for companies seeking reliable and ethical testing solutions.

Invitro International has achieved several significant milestones in its history. Some notable achievements include the development of innovative medical devices and technologies, successful collaborations with leading industry partners, and the expansion of its global presence. The company's breakthrough research and development efforts have led to the introduction of groundbreaking diagnostics solutions, ultimately improving patient outcomes. Invitro International's commitment to excellence and continuous innovation has solidified its position as a leader in the industry. With a strong focus on customer satisfaction and quality, Invitro International continues to create new milestones and advance the field of medical diagnostics.

Invitro International is primarily present in the United States and Canada.

Invitro International represents a commitment to scientific innovation, integrity, and global impact. With a mission to provide advanced in vitro diagnostic solutions, Invitro International prioritizes accuracy, reliability, and the highest standards of quality in its products and services. The company's corporate philosophy revolves around collaboration, research-driven development, and customer-centricity, aiming to empower medical professionals and improve patient outcomes worldwide. By combining cutting-edge technology and extensive industry expertise, Invitro International strives to revolutionize the field of diagnostics, contributing to advancements in medical research and delivering valuable solutions to meet the evolving needs of healthcare providers.

Nykyisellä valuuttakurssilla Invitro International-osake noteerataan hintaan 0,05 EUR (0,06 USD).

Invitro International is a globally active company specialized in the development and marketing of innovative products for pharmaceutical and biomedical research. The company has been active in this field for over 20 years and has earned an outstanding reputation for the quality and reliability of its products. Invitro International offers a wide range of products and services divided into three main categories: cell culture, toxicology, and genotoxicology. Each of these categories includes a variety of specialized products and services tailored to the needs of pharmaceutical and biomedical research. Invitro International's cell culture products include cell lines, cell and tissue models, culture systems, reagents, and media. These products have a wide range of applications in research, particularly in the study of diseases such as cancer, diabetes, and Alzheimer's. The toxicology products of Invitro International are used to evaluate the toxicity of chemicals and drugs. The product range includes cell and tissue models specifically designed for toxicity testing, as well as specialized analysis devices and software. Invitro International's genotoxicology products are used to assess the harmful effects of chemicals and drugs on the genetic material. These products include tests for gene mutations and chromosomal aberrations, as well as specialized analysis devices and software. Invitro International also offers services such as research support, test procedure development, and consulting services tailored to the specific needs of its customers. These services are provided by highly qualified and experienced researchers and laboratory personnel equipped with the latest technologies and methods. Invitro International has earned a reputation as an innovative company that continuously develops new products and technologies to meet the needs of its customers. The company invests heavily in research and development to ensure it stays at the forefront of science. Invitro International has a global network of distribution partners and distributors who sell and support its products and services worldwide. The company is headquartered in the USA but also has subsidiaries and branches in Europe and Asia. Overall, Invitro International is a leading company in pharmaceutical and biomedical research, offering a wide range of high-quality products and services tailored to the specific needs of its customers. The company is committed to researching and developing new products and technologies to ensure it continues to provide innovative solutions to its customers in the future.

Liikevaihtoa ei voida laskea Invitro International:lle tällä hetkellä.

Voittoa ei voida laskea Invitro International:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Invitro International:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Invitro International:lle tällä hetkellä.

Invitro International:n Eulpool-laatuscore on 4/10.

Invitro International:n ISIN on US4618531036. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Invitro International:n WKN on 886451. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Invitro International:n ticker on IVRO. Tämä pörssinoteeraus käytetään Invitro International-osakkeiden kauppaan pörssissä.